1. Home
  2. AKR vs CELC Comparison

AKR vs CELC Comparison

Compare AKR & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKR
  • CELC
  • Stock Information
  • Founded
  • AKR 1993
  • CELC 2011
  • Country
  • AKR United States
  • CELC United States
  • Employees
  • AKR N/A
  • CELC N/A
  • Industry
  • AKR Real Estate Investment Trusts
  • CELC Medical Specialities
  • Sector
  • AKR Real Estate
  • CELC Health Care
  • Exchange
  • AKR Nasdaq
  • CELC Nasdaq
  • Market Cap
  • AKR 2.6B
  • CELC 2.8B
  • IPO Year
  • AKR 1993
  • CELC 2017
  • Fundamental
  • Price
  • AKR $19.12
  • CELC $74.44
  • Analyst Decision
  • AKR Strong Buy
  • CELC Strong Buy
  • Analyst Count
  • AKR 3
  • CELC 5
  • Target Price
  • AKR $22.33
  • CELC $69.40
  • AVG Volume (30 Days)
  • AKR 1.2M
  • CELC 1.6M
  • Earning Date
  • AKR 10-28-2025
  • CELC 11-13-2025
  • Dividend Yield
  • AKR 4.18%
  • CELC N/A
  • EPS Growth
  • AKR 1674.20
  • CELC N/A
  • EPS
  • AKR 0.12
  • CELC N/A
  • Revenue
  • AKR $415,477,000.00
  • CELC N/A
  • Revenue This Year
  • AKR N/A
  • CELC N/A
  • Revenue Next Year
  • AKR $10.79
  • CELC N/A
  • P/E Ratio
  • AKR $154.86
  • CELC N/A
  • Revenue Growth
  • AKR 13.78
  • CELC N/A
  • 52 Week Low
  • AKR $16.98
  • CELC $7.58
  • 52 Week High
  • AKR $26.29
  • CELC $83.00
  • Technical
  • Relative Strength Index (RSI)
  • AKR 39.22
  • CELC 70.36
  • Support Level
  • AKR $19.02
  • CELC $64.61
  • Resistance Level
  • AKR $20.08
  • CELC $80.13
  • Average True Range (ATR)
  • AKR 0.40
  • CELC 5.00
  • MACD
  • AKR 0.00
  • CELC 2.42
  • Stochastic Oscillator
  • AKR 13.51
  • CELC 77.38

About AKR Acadia Realty Trust

Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: Core Portfolio segment consists primarily of high-quality retail properties located primarily in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds primarily retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: